For Teens, AI Dietary Recommendations Deviate From Dietitian Plans
via HealthDayTHURSDAY, March 12, 2026 -- For adolescents, artificial intelligence (AI) model-generated diets exhibit clinically significant deviations from dietitian reference plans, according to a study published online March 12 in Frontiers in Nutrition.
Ayşe Betül Bilen, from Istanbul Atlas University, and colleagues evaluated the clinical validity of AI by comparing the nutritional content of diets generated by different AI models with dietitian reference plans. In the cross-sectional and comparative study, 60 three-day diet plans were generated in two sessions by five AI models for four standardized adolescent profiles. For each profile, a dietitian reference plan was prepared.
The researchers found that AI models tended to systematically undercalculate energy, protein, lipid, and carbohydrate (mean bias, +695 kcal, +19.9 g, +15.8 g, and +114.6 g, respectively). In macronutrient percentages, protein and lipid ratios were above (21.5 to 23.7 percent and 41.5 to 44.5 percent, respectively) and carbohydrate ratios were below (32.4 to 36.3 percent) the recommended adolescent guidelines. Micronutrient contents varied significantly between models; none of the models showed consistent proximity to the dietitian for any nutrients.
"Adolescence is a critical period for physical growth, bone development, and cognitive maturation," Bilen said in a statement. "Lower energy and carbohydrate intake, combined with increased protein and fat ratios, may pose risks during the adolescent growth period."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-13 01:48
Read more
- In Utero Exposure to Forever Chemicals Higher Than Previously Thought
- Breast Cancer Cases, Deaths Expected To Rise Worldwide
- BJ’s Wholesale Club Issues Salmon Recall Across Seven East Coast States
- SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions